News

TechMARK movers: Alizyme jumps on licence deal

27 June 2008 15:16:00

Alizyme rallied on news that it could net up to €42.75m after it granted an exclusive licence to Norgine for the rights to market Colal-Pred, used to treat ulcerative colitis, in Europe, South Africa, Australia and New Zealand.

The UK drug developer will receive £2m upfront and another €40.75m based on the future development and sales milestones.

Gastroenterology-focused Norgine will cover all commercialisation costs and will pay double digit royalty rates to Alizyme that increase with higher annual net sales levels.

Security alarms specialist Visonic expects to report a 'substantial improvement' in profit for the six months to 30 June, despite the continuing adverse impact of the strength of the Israeli shekel.

The group said sales in the second quarter of its core business of security and home management are estimated to be up about 19% in comparison with the corresponding period in 2007, with increased sales to almost all its territories and particularly robust growth in Europe.

"I am delighted to report that Visonic's strategy of driving our sales growth through mass market channels, primarily partnerships with leading security and utility companies, is proving successful, as these excellent sales trends show,"said chief executive and president Avigdor Shachrai.

FTSE TechMARK - Risers
Ardana (ARA) 6.50p +30.00%
Alizyme (AZM) 22.25p +7.23%
Visonic (VSC) 53.00p +6.00%
Oxford Biomedica (OXB) 23.25p +5.68%
AEA Technology (AAT) 68.75p +4.17%
Ark Therapeutics (AKT) 55.00p +2.80%
BTG (BGC) 180.50p +2.12%
Renovo Group (RNVO) 40.00p +1.91%
Xaar (XAR) 198.50p +1.79%
ProStrakan (PSK) 79.25p +1.28%

FTSE TechMARK - Fallers
Protherics (PTI) 29.50p -7.09%
Dialight (DIA) 139.00p -6.71%
Emblaze (BLZ) 37.50p -6.25%
Thus Group (THUS) 143.50p -5.28%
Skyepharma (SKP) 6.25p -4.29%
Imagination Technologies (IMG) 70.00p -4.11%
Computacenter (CCC) 129.00p -3.91%
Horizon Technology (HOR) 89.00p -3.78%
Biocompatibles International (BII) 145.00p -3.17%
RM Group (RM.) 185.75p -2.88%

All data suppied by Digital Look (15 minute delay)




Risk Warning

There is an extra risk of losing money when shares are bought in some smaller companies including 'Penny Shares'. There is a big difference between the buying price and the selling price of these shares. If they have to be sold immediately, you may get back much less than you paid for them or you may have difficulty in selling them. Past performance is not a reliable indicator of future results. The price may change quickly and it may go down as well as up. You could lose every penny put into a particular share.

The information contained above has been compiled from documented sources which are believed to be reliable but, due to their very nature, are subject to a degree of historical inaccuracy and have not been independently verified and cannot be guaranteed. The pages on this website are provided for information only. City Equities Limited will not accept responsibility for loss incurred by any person or body acting, or refraining from acting, as a result of information and/or opinions given anywhere on this website. Issued by City Equities Limited, Aldermary House, 10-15 Queen Street, London, EC4N 1TY. Registered in England. Registered No. 2742847. Registered Address: Amwell House, 19 Amwell Street, Hoddeson, Herts. EN11 8TS. City Equities Limited is Authorised and regulated by the Financial Services Authority. Registration No. 155051.